Maninder Kour Bali, MD | |
5500 S Sycamore St, Littleton, CO 80120-8201 | |
(720) 707-6363 | |
Not Available |
Full Name | Maninder Kour Bali |
---|---|
Gender | Female |
Speciality | Psychiatry |
Experience | 19 Years |
Location | 5500 S Sycamore St, Littleton, Colorado |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528220266 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 003107 (Georgia) | Secondary |
2084P0800X | Psychiatry & Neurology - Psychiatry | MD50917 (Colorado) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Arapahoe Mental Health Center Inc | 7315850708 | 73 |
News Archive
A new study at Johns Hopkins finds that many hospitalized patients prefer visits from their own physician to those of the physicians on duty, even when those "visits" are virtual "telerounds."
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act.
OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.
Criticisms of COVID-19 models by Democratic elites in May 2020 appeared to undermine public support for the models' use - and trust in science more broadly - according to a series of survey experiments conducted with the participation of more than 6,000 Americans.
› Verified 9 days ago
Entity Name | Arapahoe Mental Health Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1437763968 PECOS PAC ID: 7315850708 Enrollment ID: O20031111000581 |
News Archive
A new study at Johns Hopkins finds that many hospitalized patients prefer visits from their own physician to those of the physicians on duty, even when those "visits" are virtual "telerounds."
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act.
OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.
Criticisms of COVID-19 models by Democratic elites in May 2020 appeared to undermine public support for the models' use - and trust in science more broadly - according to a series of survey experiments conducted with the participation of more than 6,000 Americans.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Maninder Kour Bali, MD 155 Inverness Dr W, West Suite 200, Englewood, CO 80112-5095 Ph: () - | Maninder Kour Bali, MD 5500 S Sycamore St, Littleton, CO 80120-8201 Ph: (720) 707-6363 |
News Archive
A new study at Johns Hopkins finds that many hospitalized patients prefer visits from their own physician to those of the physicians on duty, even when those "visits" are virtual "telerounds."
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act.
OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.
Criticisms of COVID-19 models by Democratic elites in May 2020 appeared to undermine public support for the models' use - and trust in science more broadly - according to a series of survey experiments conducted with the participation of more than 6,000 Americans.
› Verified 9 days ago
Dr. Christina Peragine, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 5984 S Prince St Ste 101, Littleton, CO 80120 Phone: 303-738-1021 Fax: 303-738-1047 | |
Lindsey Dianne Rutledge, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 8340 Sangre De Cristo Rd, Suite 209, Littleton, CO 80127 Phone: 720-589-0528 | |
Dr. James Robert Digioia, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1510 W Canal Ct Ste 2500, Littleton, CO 80120 Phone: 303-338-4545 | |
Dr. Michael Anthony Leander Johnson, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 4 W Dry Creek Cir Ste 150, Littleton, CO 80120 Phone: 303-730-2883 Fax: 303-730-2471 | |
Dr. John Frazier Alston, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 5921 Middlefield Rd Ste 201, Littleton, CO 80123 Phone: 303-916-5097 | |
Dr. Mihaela G Alexander, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4 W Dry Creek Cir, Ste 150, Littleton, CO 80120 Phone: 303-730-2883 Fax: 303-730-2471 | |
Shefali Jindal, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 5500 S Sycamore St, Littleton, CO 80120 Phone: 303-730-8858 |